News & Events
News & Events
Institut Pasteur Korea Joins INTERCEPTOR as the First Northeast Asian Partner in the Global High-Containment Laboratory Network
2026-05-15
Institut Pasteur Korea Joins INTERCEPTOR as the First Northeast Asian Partner in the Global High-Containment Laboratory Network
– Sharing infrastructure, expertise, and resources among high-containment laboratories –
– Showcasing research capabilities at the Paris General Assembly; expected to play a leading role in shaping INTERCEPTOR II –
– Showcasing research capabilities at the Paris General Assembly; expected to play a leading role in shaping INTERCEPTOR II –
.jpg)
A representative from the Institut Pasteur Korea poses for a commemorative photo with global partners at the INTERCEPTOR Annual Meeting held in Paris, France, on March 22.
(May. 15, 2026, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) has joined the global collaborative network on high-containment research infrastructures, INTERCEPTOR (INTERnational Cooperation of high containment research infrastructures: from Epidemic Preparedness TO Response), as an Associated Partner, becoming the first institution from Northeast Asia to participate in the project.
IPK officially launched its participation by attending the INTERCEPTOR annual meeting held on March 22–23 in Paris, France. The meeting, organized by ERINHA (European Research Infrastructure on Highly Pathogenic Agents), brought together leading high-containment research institutions. During the session dedicated to new partners, IPK presented its research capabilities, generating strong interest and multiple collaboration inquiries.
INTERCEPTOR is a project funded under the European Union’s flagship research and innovation programme, Horizon Europe. It aims to strengthen global preparedness and response to infectious diseases by enabling the sharing of critical resources among high-containment laboratories (BSL-3 and BSL-4) and by establishing a coordinated network to address highly pathogenic agents.
At the annual meeting, participants reviewed the achievements of existing working groups and discussed strategic directions for the follow-up initiative, INTERCEPTOR II. IPK is expected to actively contribute to the development of future strategies and project planning.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “Building on IPK’s advanced capabilities in operating high-containment laboratories and its expertise in vaccine and therapeutic research for infectious diseases, we have continuously expanded our research capacity. Based on the strong interest and expectations confirmed at the annual meeting, we aim to play a leading role in shaping follow-up initiatives such as INTERCEPTOR II and contribute to advancing global preparedness against infectious diseases.”
(May. 15, 2026, Gyeonggi-do, Rep. of Korea) Institut Pasteur Korea (IPK) has joined the global collaborative network on high-containment research infrastructures, INTERCEPTOR (INTERnational Cooperation of high containment research infrastructures: from Epidemic Preparedness TO Response), as an Associated Partner, becoming the first institution from Northeast Asia to participate in the project.
IPK officially launched its participation by attending the INTERCEPTOR annual meeting held on March 22–23 in Paris, France. The meeting, organized by ERINHA (European Research Infrastructure on Highly Pathogenic Agents), brought together leading high-containment research institutions. During the session dedicated to new partners, IPK presented its research capabilities, generating strong interest and multiple collaboration inquiries.
INTERCEPTOR is a project funded under the European Union’s flagship research and innovation programme, Horizon Europe. It aims to strengthen global preparedness and response to infectious diseases by enabling the sharing of critical resources among high-containment laboratories (BSL-3 and BSL-4) and by establishing a coordinated network to address highly pathogenic agents.
At the annual meeting, participants reviewed the achievements of existing working groups and discussed strategic directions for the follow-up initiative, INTERCEPTOR II. IPK is expected to actively contribute to the development of future strategies and project planning.
Sung Key Jang, CEO of Institut Pasteur Korea, stated, “Building on IPK’s advanced capabilities in operating high-containment laboratories and its expertise in vaccine and therapeutic research for infectious diseases, we have continuously expanded our research capacity. Based on the strong interest and expectations confirmed at the annual meeting, we aim to play a leading role in shaping follow-up initiatives such as INTERCEPTOR II and contribute to advancing global preparedness against infectious diseases.”